Baxalta Inc. (BXLT) said it has dosed the first patient in its Phase 1, first-in-human clinical trial of BAX 826, a recombinant Factor VIII or rFVIII treatment for hemophilia A that uses proprietary polysialic acid (PSA) technology to extend its circulating half-life.
from RTT - Biotech http://ift.tt/1QxjyDA
via IFTTT
No comments:
Post a Comment